Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA bill carries device language

This article was originally published in The Gray Sheet

Executive Summary

Prescription Drug User Fee Act reauthorization legislation, set for markup April 18 in the Senate Health, Education, Labor & Pensions Committee, would establish a publicly accessible database of all postmarket surveillances and studies of PMA-approved and 510(k)-cleared medical devices. The legislative language comes after CDRH has already voluntarily launched a public 1Web site tracking postmarket study progress (2"The Gray Sheet" April 2, 2007, p. 26). The bill also includes language, originally introduced by Senator Chris Dodd, D-Conn., last month, that would link pediatric device innovators with funding sources, allow profit for humanitarian-device-exempted devices and mandate postmarket surveillance studies for pediatric devices (3"The Gray Sheet" April 2, 2007, p. 25). In addition, the legislation formally encourages reauthorization of the Medical Device User Fee and Modernization Act of 2002, which, like the drug user fee program, needs to be reauthorized before Sept. 30 when it is set to expire...

You may also be interested in...

No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6

A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6

Dodd Aims For Quick Passage Of Pediatric Device Legislation

Sen. Christopher Dodd, D-Conn., is pushing for quick action on legislation to provide incentives for the development of pediatric medical devices

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts